NEW YORK (360Dx) – Akers Biosciences announced today that it has signed a three-year agreement with the Greater New York Hospital Association — a trade and group purchasing association representing hospitals and healthcare systems in New York, New Jersey, Connecticut, and Rhode Island.

As part of the agreement, Akers Biosciences will market its rapid tests for heparin-induced thrombocytopenia to the association’s 300 hospitals.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.